General description
Despite ongoing efforts to understand growth and signaling pathways in head and neck squamous cell carcinoma (HNSCC), patient outcomes have remained largely unchanged in recent decades. A significant barrier to understanding and studying immune responses in the context of cancer in recent years has been the lack of available syngeneic mouse models. Xenograft approaches have historically been popular models, but they unfortunately do not model important adapative immunity responses.The MOC2 cell line expresses CD44, which has been implicated as a cancer stem cell marker that typically characterizes tumors with higher resistance to therapeutic treatment, at a higher level when compared to the MOC1 cell line. The MOC2 cell line generates a tumor microenvironment with lower CD8+ T cell levels The MOC2 cell line exhibits a more aggressive growth pattern than the more indolent growth observed with MOC1 cells.The MOC cell lines have expanded our understanding of CXCL14 downregulation in metastatic lymph nodes. Previously, CXCL14 expression had been associated with T-cell associated mechanisms for tumor suppression. Tumor Infiltrating Lymphocyte (TIL) studies using MOC1 and MOC2 have found a cell-specific association in Oral Squamous Cell Carcinomas (OSCCs) involving CXCL14 downregulation resulting in TIL increase which leads to tumor suppression.The MOC group of cell lines contained common HNSCC mutations in addition to human-related OSCC driver pathways. All MOC lines share RAS pathway mutations and MOC22 was found to have HRAS mutations which is relevant in relation to human HRAS-mutant OSCC groups. Source: The MOC2 cell line was derived from carcinogen-induced oral tumors in immunocompetent C57BL/6 mice.References: 1. Judd, N. P., Allen, C. T., Winkler, A. E., & Uppaluri, R. (2012). Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngology--Head and Neck Surgery, 147(3), 493-500.2. Parikh, A., Shin, J., Faquin, W., Lin, D. T., Tirosh, I., Sunwoo, J. B., & Puram, S. V. (2020). Malignant cell-specific CXCL14 promotes tumor lymphocyte infiltration in oral cavity squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 8(2).3. Onken, M. D., Winkler, A. E., Kanchi, K. L., Chalivendra, V., Law, J. H., Rickert, C. G., ... & Uppaluri, R. (2014). A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clinical Cancer Research, 20(11), 2873-2884.
Application
Each vial contains >1X106 viable cells.
MOC2 cells are verified to be of mouse origin and negative for human, rat, Chinese hamster, Golden Syrian hamster, and non-human primate interspecies contamination, as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
Cells tested negative for infectious diseases against a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
Cells tested negative for mycoplasma.
Features and Benefits
The MOC (Mouse Oral Cancer) cell lines provide a syngeneic HNSCC cancer model that can be transplanted into C57BL/6 mice. These lines are important models for immune cell infiltration applications. The MOC lines have been utilized to compare and identify potential clinical scenarios that are applicable to human Oral Squamous Cell Carcinoma.The MOC2 cell line was derived from primary tumors in a C57BL/6 WT mouse and demonstrates an aggressive growth phenotype and decreased MHC I expression.
Preparation Note
MOC2 cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting cell marker expression and functionality.
Other Notes
Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact
[email protected].
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
